Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma
Nuvation Bio Inc. Class A (NUVB)
Company Research
Source: Business Wire
Protocol amendment to change SIGMA from a Phase 2 to a Phase 3 study now completeThe currently enrolling SIGMA trial will now include patients with grade 2 astrocytoma with high-risk features in the maintenance setting, in addition to previously eligible patients with high-grade astrocytomaA new exploratory cohort has also been added for patients with grade 3 oligodendroglioma in the post-surgical settingBroad patient population in SIGMA represents most forms of IDH1-mutant glioma that do not have an FDA-approved targeted treatment option NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced finalization of a protocol amendment to the ongoing global SIGMA study (also known as G203; NCT05303519) of safusidenib that expands it to a Phase 3 trial. SIGMA is evaluating the efficacy and safety of safusidenib versus placebo for the maintenance treatment of patients with
Show less
Read more
Impact Snapshot
Event Time:
NUVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVB alerts
High impacting Nuvation Bio Inc. Class A news events
Weekly update
A roundup of the hottest topics
NUVB
News
- Nuvation Bio (NYSE:NUVB) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.MarketBeat
- Nuvation Bio: Rollout Data Of Ibtrozi Support A Modest Buy [Seeking Alpha]Seeking Alpha
- Assessing Nuvation Bio (NUVB) Valuation After Bullish Analyst Calls On Ibtrozi And mIDH1 Glioma Potential [Yahoo! Finance]Yahoo! Finance
- Truist Highlights Nuvation Bio's (NUVB) Ibtrozi's Robust Market Uptake and Lead Over Competitors [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio (NYSE:NUVB) was given a new $13.00 price target on by analysts at Truist Financial Corporation.MarketBeat
NUVB
Earnings
- 11/3/25 - Beat
NUVB
Sec Filings
- 2/10/26 - Form 25-NSE
- 1/12/26 - Form 8-K
- 12/3/25 - Form 4
- NUVB's page on the SEC website